ArticleScientific reports2025
Predicting metabolic dysfunction associated steatotic liver disease using explainable machine learning methods.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic accuracy of artificial intelligence models for imaging detection of hepatic steatosis through systematic review and meta analysis.Scientific reports · 2025Pooled it
- Plasma proteomics framework predicts metabolic dysfunction-associated steatotic liver disease up to 16 years before onset.Nature aging · 2026Article
- Article
- Artificial Intelligence in Population-Level Gastroenterology and Hepatology: A Comprehensive Review of Public Health Applications and Quantitative Impact.Digestive diseases and sciences · 2026Review
- Artificial intelligence and digital transformation of gastroenterology and hepatology: A critical review of clinical applications and future challenges.World journal of hepatology · 2026Review
- Integrating body composition analysis and machine learning for non-invasive identification of metabolic dysfunction-associated fatty liver disease: a large-scale health examination-based study.Scientific reports · 2026Article
- Artificial intelligence in metabolic dysfunction-associated steatotic liver disease: Transforming diagnosis and therapeutic approaches.World journal of gastroenterology · 2026Review
- Harnessing AI-driven approaches for detecting metabolic dysfunction-associated steatotic liver disease, assessing fibrosis, and stratifying hepatocellular carcinoma risk: a scoping review.Frontiers in oncology · 2026Review
- Developing a non-invasive algorithm for the diagnosis of steatotic liver disease in primary healthcare: a retrospective cohort study.BMJ health & care informatics · 2025Article
- Artificial intelligence in metabolic dysfunction-associated steatotic liver disease: Machine learning for non-invasive diagnosis and risk stratification.World journal of hepatology · 2025Review
- Image analysis of cardiac hepatopathy secondary to heart failure: Machine learningWorld journal of gastroenterology · 2025Article
- Predicting the risk of metabolic-associated fatty liver disease in the elderly population in China: construction and evaluation of interpretable machine learning models.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Early and accurate identification of patients at high risk of metabolic dysfunction-associated steatotic liver disease (MASLD) is critical to prevent and improve prognosis potentially. We aimed to develop and validate an explainable prediction model based on machine learning (ML) approaches for MASLD among the adult population. The national cross-sectional study collected data from the National Health and Nutrition Examination Survey from 2017 to 2020, consisting of 13,436 participants, who were randomly split into 70% training, 20% internal validation, and 10% external validation cohorts. MASLD was defined based on transient elastography and cardiometabolic risk factors. With 50 medical characteristics easily obtained, six ML algorithms were used to develop prediction models. Several evaluation parameters were used to compare the predictive performance, including the area under the receiver-operating-characteristic curve (AUC) and precision-recall (P-R) curve. The recursive feature elimination method was applied to select the optimal feature subset. The Shapley Additive exPlanations method offered global and local explanations for the model. The random forest (RF) model performed best in discriminative ability among 6 ML models, and the optimal 10-feature RF model was finally chosen. The final model could accurately predict MASLD in internal and external validation cohorts (AUC: 0.928, 0.918; area under P-R curve: 0.876, 0.863, respectively). The final model performed better than each of the traditional risk indicators for MASLD. An explainable 10-feature prediction model with excellent discrimination and calibration performance was successfully developed and validated for MASLD based on clinical data easily extracted using an RF algorithm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.